摘要
微小RNA（miRNAs,miR）是一类长约21-22核苷酸的单链非蛋白编码小RNA分子。在肝脏,多种miRNA的表型改变或表达异常均可在基因水平影响肝炎病毒的复制,靶向调控肝组织炎症向肝纤维化、肝硬化,甚至原发性肝癌进展,并因此成为一类新型肿瘤相关基因;不仅如此,miRNAs数量或功能异常还通过干扰胰岛素信号传导,诱导胰岛素抵抗发生,从而影响机体正常脂质代谢,促进脂肪性肝病的形成。因此,寻找特效的药物或方法,纠正肝细胞内miRNAs异常,将成为人类攻克多种慢性肝病的一类新型重要手段。
MicroRNAs （miRNAs, m/R） is a class of 21 -22 nt small non-protein-coding single strand RNA molecules. In the liver, the phenotypic alternation or expressed abnormality of many miRNAs can influence the hepatitis virus replication at the gene level, which would provocate the development from hepatitis to hepatic fibrosis, cirrhosis, and even primary hepatic carcinoma on target. And so, several miRNAs are confirmed to be a new class of related gene to carcinoma. Furthermore, the dysfunction or abnormal quantity of miRNAs will promote the formation of fatty liver disease by interfering with signal transduction of insulin, inducing insulin resistance and then influencing normal metabolism of endosomatic lipid, Therefore, the specific medicine or methods, which might retrieve the expression or function of miRNAs in the hepatocytes, will provide a new valuable method to manage human liver disease.
出处
《基础医学与临床》
CSCD
北大核心
2009年第2期216-219,共4页
Basic and Clinical Medicine
